🇺🇸 Jascayd in United States

FDA authorised Jascayd on 7 October 2025

Marketing authorisations

FDA — authorised 7 October 2025

Application: NDA218764
Marketing authorisation holder: BOEHRINGER INGELHEIM
Local brand name: JASCAYD
Indication: TABLET — ORAL
Status: approved

The FDA granted marketing authorisation to Jascayd, a drug developed by Boehringer Ingelheim, on 26 February 2026. The marketing authorisation holder is Boehringer Ingelheim, and the application number is NDA218764. The drug was approved through the standard expedited pathway.

Read official source →

FDA — authorised 19 December 2025

Application: NDA220449
Marketing authorisation holder: BOEHRINGER INGELHEIM
Local brand name: JASCAYD
Indication: TABLET — ORAL
Status: approved

Read official source →

FDA

Marketing authorisation holder: BOEHRINGER INGELHEIM
Status: approved

Jascayd in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in United States

Frequently asked questions

Is Jascayd approved in United States?

Yes. FDA authorised it on 7 October 2025; FDA authorised it on 19 December 2025; FDA has authorised it.

Who is the marketing authorisation holder for Jascayd in United States?

BOEHRINGER INGELHEIM holds the US marketing authorisation.